Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients
15 auth.
E. Krenning,
D. Kwekkeboom,
W. Bakker,
W. Breeman,
P. Kooij,
H. Oei,
M. Hagen,
P. Postema,
M. Jong,
J. Reubi,
...
T. Visser,
A. Reijs,
L. Hofland,
J. Koper,
S. Lamberts
|
10 |
1993 |
10
1993
|
Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use
7 auth.
J. Reubi,
J. Schär,
B. Waser,
S. Wenger,
A. Heppeler,
J. Schmitt,
...
H. Mäcke
|
10 |
2000 |
10
2000
|
Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data
11 auth.
M. Hofmann,
H. Maecke,
Börner Ar,
E. Weckesser,
P. Schöffski,
M. Oei,
...
J. Schumacher,
M. Henze,
A. Heppeler,
G. Meyer,
W. Knapp
|
9 |
2001 |
9
2001
|
Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer
S. Adams,
R. Baum,
T. Stuckensen,
K. Bitter,
G. Hör
|
8 |
1998 |
8
1998
|
Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands
J. Reubi,
B. Waser,
J. Schaer,
J. Laissue
|
8 |
2001 |
8
2001
|
Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients
L. Strauss
|
8 |
1996 |
8
1996
|
Yttrium-90 DOTATOC: first clinical results
8 auth.
A. Otte,
R. Herrmann,
A. Heppeler,
M. Béhé,
E. Jermann,
P. Powell,
...
H. Maecke,
J. Muller
|
8 |
1999 |
8
1999
|
Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours
S. Adams,
R. Baum,
T. Rink,
P. Schumm-Dräger,
K. Usadel,
G. Hör
|
8 |
1997 |
8
1997
|
[177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients
10 auth.
D. Kwekkeboom,
W. Bakker,
P. Kooij,
M. Konijnenberg,
A. Srinivasan,
J. Erion,
...
Michelle A. Schmidt,
J. L. Bugaj,
M. de Jong,
E. Krenning
|
8 |
2001 |
8
2001
|
Radioimmunotherapy with alpha-emitting nuclides
7 auth.
M. McDevitt,
G. Sgouros,
R. Finn,
J. Humm,
J. Jurcic,
S. Larson,
...
D. Scheinberg
|
8 |
1998 |
8
1998
|
O-(2-[18F]Fluoroethyl)-l-tyrosine and l-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study
9 auth.
W. Weber,
H. Wester,
A. Grosu,
M. Herz,
B. Dzewas,
H. Feldmann,
...
M. Molls,
G. Stöcklin,
M. Schwaiger
|
8 |
2000 |
8
2000
|
FDG-PET for clinical use
S. Reske,
J. Kotzerke
|
8 |
2001 |
8
2001
|
Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study
13 auth.
F. Grünwald,
T. Kälicke,
U. Feine,
R. Lietzenmayer,
K. Scheidhauer,
M. Dietlein,
O. Schober,
H. Lerch,
K. Brandt-Mainz,
W. Burchert,
...
G. Hiltermann,
U. Cremerius,
H. Biersack
|
8 |
1999 |
8
1999
|
Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose
8 auth.
P. Rigo,
P. Paulus,
B. Kaschten,
R. Hustinx,
T. Bury,
G. Jerusalem,
...
T. Benoit,
J. Foidart-Willems
|
8 |
1996 |
8
1996
|
Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer
T. Bury,
A. Barreto,
F. Daenen,
N. Barthélémy,
B. Ghaye,
P. Rigo
|
8 |
1998 |
8
1998
|
Nitroimidazoles and imaging hypoxia
A. Nunn,
K. Linder,
H. Strauss
|
8 |
1995 |
8
1995
|
